About Pricing FAQs Providers Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Clinical Trials in Atlanta | 19,805 Studies Near You | Clareo Health

Clinical Trials LocationsAtlanta

Clinical Trials in Atlanta

Discover 19,805 clinical trials near Atlanta, Georgia. Find research studies in your area.

Browse by condition:

Breast Cancer Lung Cancer Prostate Cancer Colorectal Cancer Melanoma Leukemia Lymphoma Pancreatic Cancer

Filters

Sort by

Status

Recruiting(Enrolling)

Not yet recruiting

Active, not recruiting

Enrolling by invitation(Enrolling)

Completed

Terminated

Phase

Early Phase 1

Phase 1

Phase 1/Phase 2

Phase 2

Phase 2/Phase 3

Phase 3

Phase 4

Not Applicable

Eligibility

Accepts healthy volunteers

Showing 18461-18480 of 19,805 trials

COMPLETEDPhase 2< 1 mile

A Study to Evaluate and Compare Injections of Autologous Dermal Cells Into the Balding Scalp of Subjects With Hair Loss

NCT01451099

Evaluate the ability of Ji Gami(TM) DO to induce hair growth in male and female subjects with hair loss.

Androgenetic AlopeciaMale Pattern BaldnessFemale Pattern Baldness

Aderans Research Institute21 participantsStarted Jun 2009

Atlanta, Georgia, United States • Chevy Chase, Maryland, United States • Boston, Massachusetts, United States +3 more locations

COMPLETEDPhase 3< 1 mile

Study to Compare Pioglitazone and Rosiglitazone in Subjects With Type 2 Diabetes Mellitus and Dyslipidemia

NCT00331487

Efficacy comparison of Pioglitazone, once daily (QD), to Rosiglitazone in participants with Type 2 Diabetes

Diabetes Mellitus

Takeda719 participantsStarted Sep 2000

Anniston, Alabama, United States • Birmingham, Alabama, United States • Tucson, Arizona, United States +64 more locations

Find Trials by Condition in Atlanta

Breast Cancerin Atlanta Lung Cancerin Atlanta Prostate Cancerin Atlanta Colorectal Cancerin Atlanta Melanomain Atlanta Leukemiain Atlanta Lymphomain Atlanta Pancreatic Cancerin Atlanta Ovarian Cancerin Atlanta Brain Cancerin Atlanta Diabetes

Data from ClinicalTrials.govTerms

COMPLETEDPhase 3< 1 mile

Safety and Efficacy of Ramelteon in Elderly Subjects With Chronic Insomnia.

NCT00671294

This purpose of this study is to assess the efficacy and safety of Ramelteon, once daily (QD), in elderly subjects with chronic insomnia.

Chronic Insomnia

Takeda100 participantsStarted Oct 2002

Hot Springs, Arkansas, United States • Irvine, California, United States • Palm Springs, California, United States +15 more locations

COMPLETEDPhase 3< 1 mile

Efficacy of Ramelteon on Transient Insomnia in Healthy Adults

NCT00671398

The purpose of this study is to evaluate the safety and efficacy of Ramelteon, once daily (QD), in healthy subjects within a sleep lab.

Transient Insomnia

Takeda289 participantsStarted Dec 2002

Palm Springs, California, United States • San Diego, California, United States • Miami, Florida, United States +9 more locations

COMPLETEDPhase 3< 1 mile

Efficacy of Ramelteon in Subjects With Chronic Insomnia

NCT00671086

The purpose of this study is to determine the long-term safety of Ramelteon, once daily (QD), in subjects with chronic insomnia.

Sleep Initiation and Maintenance Disorders

Takeda1,213 participantsStarted Feb 2003

Birmingham, Alabama, United States • Mobile, Alabama, United States • Phoenix, Arizona, United States +119 more locations

COMPLETEDPhase 3< 1 mile

Open-Label Extension Study to Evaluate the Safety, Tolerability and Activity of Oral Fampridine-SR in Patients With Multiple Sclerosis Who Participated in the MS-F204 Trial

NCT00649792

The purpose of the study is to evaluate the safety, tolerability and activity of Fampridine-SR when administered for up to 36 additional months in patients who previously participated in the MS-F204 study or until it becomes commercially available, whichever comes first.

Multiple Sclerosis

Acorda Therapeutics214 participantsStarted Aug 2007

Phoenix, Arizona, United States • Phoenix, Arizona, United States • Fayetteville, Arkansas, United States +39 more locations

COMPLETEDPhase 2< 1 mile

Safety and Efficacy of Ramelteon in Healthy Subjects

NCT00671190

The purpose of this study is to determine the phase-advance in circadian rhythms in healthy adults subjects taking ramelteon, once daily (QD).

Takeda75 participantsStarted Mar 2005

Hot Springs, Arkansas, United States • Los Angeles, California, United States • San Diego, California, United States +10 more locations

COMPLETEDPhase 3< 1 mile

Study of Abatacept (BMS-188667) in Subjects With Active Rheumatoid Arthritis on Background Non-biologic DMARDS (Disease Modifying Antirheumatic Drugs) Who Have an Inadequate Response to Anti-TNF Therapy

NCT00124982

The purpose of this study is to summarize the safety and tolerability of abatacept during 6 months of combined treatment with one or more of the background non-biologic disease modifying anti-rheumatic drugs (DMARDs) approved for rheumatoid arthritis (RA) in subjects with active RA. Secondary objectives assessed the clinical efficacy of combination treatment, including disease activity, physical function, and quality of life outcomes.

Rheumatoid Arthritis

Bristol-Myers Squibb1,286 participantsStarted Apr 2005

Birmingham, Alabama, United States • Huntsville, Alabama, United States • Paradise Valley, Arizona, United States +145 more locations

COMPLETEDPhase 3< 1 mile

A Study of TNFerade™ Biologic With 5-FU and Radiation Therapy for First-Line Treatment of Unresectable Locally Advanced Pancreatic Cancer

NCT00051467

The primary purpose of this study is to assess the safety and effectiveness of TNFerade™ Biologic when administered concurrently with 5-FU and radiation therapy as first-line treatment of unresectable locally advanced pancreatic cancer. TNFerade™ is a replication deficient adenovirus vector containing the gene for TNF-alpha controlled by a chemoradiation inducible promoter. This allows the expression of TNF-alpha to be greatest in the area receiving radiation. TNF-alpha is a cytokine that has been shown to have potent anti-cancer activities but, due to systemic toxicity, could not be delivered at effective doses. TNFerade™ Biologic is a novel way of selective delivery of TNF-alpha to tumor cells. TNFerade™ Biologic will be injected during five weekly injection sessions, concomitant with radiation and 5-FU. TNFerade™ Biologic will be administered by direct intratumoral injection using a percutaneous approach (PTA) or endoscopic ultrasound (EUS).

Pancreatic Cancer

La Jolla, California, United States • Los Angeles, California, United States • Orange, California, United States +22 more locations

COMPLETEDPhase 3< 1 mile

Long Term Safety Study of Levalbuterol and Racemic Albuterol in Subjects Twelve Years of Age and Older With Asthma

NCT00064389

The purpose of this study is to evaluate the safety of levalbuterol as compared to racemic albuterol based on the frequencies of adverse events reporting during a 12-month period of chronic dosing of adolescent and adult subjects with asthma.

Sumitomo Pharma America, Inc.746 participantsStarted Jan 2003

Birmington, Alabama, United States • Mobile, Alabama, United States • Montgomery, Alabama, United States +93 more locations

COMPLETEDPhase 3< 1 mile

Study of Gabapentin Extended Release (G-ER)in the Treatment of Vasomotor (Hot Flashes/Hot Flushes) Symptoms in Postmenopausal Women.

NCT00777023

Depomed's Gabapentin Extended Release is an investigational, extended release formulation of gabapentin that is being studied for the treatment of hot flashes in postmenopausal women

Depomed565 participantsStarted Oct 2008

Birmingham, Alabama, United States • Chandler, Arizona, United States • Scottsdale, Arizona, United States +42 more locations

COMPLETEDPhase 3< 1 mile

A Study of Eszopiclone in Subjects With Insomnia Related to Major Depressive Disorder

NCT00368030

The purpose of this study is to evaluate subjective sleep efficacy in subjects with insomnia related to major depressive disorder.

InsomniaDepressive Disorder, Major

Sumitomo Pharma America, Inc.545 participantsStarted Jan 2004

Birmingham, Alabama, United States • Peoria, Arizona, United States • Tucson, Arizona, United States +62 more locations

COMPLETEDPhase 3< 1 mile

6-Month Chronic Efficacy & Safety Study of Eszopiclone in Adult Subjects With Primary Insomnia

NCT00352144

To evaluate the long-term efficacy of eszopiclone administered for up to 6 months in subjects with primary insomnia on subjective sleep measures, compared to placebo.

Primary Insomnia

Sumitomo Pharma America, Inc.830 participantsStarted Oct 2003

Birmingham, Alabama, United States • Huntsville, Alabama, United States • Phoenix, Arizona, United States +55 more locations

COMPLETEDPhase 322 miles

Study of Levalbuterol, Racemic Albuterol and Placebo in Subjects Twelve Years of Age and Older With Asthma

NCT00073840

The primary objective of this study is to investigate the efficacy of levalbuterol 90 ug (2 actuations, 45 ug each) versus placebo (2 actuations) in the treatment and prevention of bronchoconstriction in adolescent and adult subjects with asthma, with all treatments administered 4 times a day (QID).

Sumitomo Pharma America, Inc.386 participantsStarted Dec 2002

Oxford, Alabama, United States • Tucson, Arizona, United States • Corona, California, United States +51 more locations

COMPLETEDPhase 2140 miles

Study of Arformoterol Tartrate Inhalation Solution and Racemic Formoterol in Subjects With Mild to Moderate Chronic Obstructive Pulmonary Disease (COPD)

NCT00685529

The purpose of this study is to compare the blood levels of arformoterol tartrate inhalation solution to racemic formoterol in male and female subjects with mild to moderate Chronic Obstructive Pulmonary Disease (COPD).

Sumitomo Pharma America, Inc.24 participantsStarted Apr 2005

Long Beach, California, United States • Fort Lauderdale, Florida, United States • Raleigh, North Carolina, United States +3 more locations

COMPLETEDPhase 2140 miles

Safety of Ramelteon in Subjects With Mild to Moderate Obstructive Sleep Apnea

NCT00672061

The purpose of this study is to assess the safety of ramelteon, once daily (QD), in individuals with obstructive sleep apnea.

Sleep Apnea, Obstructive

Takeda26 participantsStarted Jul 2003

Birmingham, Alabama, United States • Palm Springs, California, United States • Santa Monica, California, United States +2 more locations

COMPLETEDPhase 4140 miles

Costs & Outcomes of Hospitalization/Treatment With Levalbuterol & Albuterol in Asthma or Chronic Obstructive Pulmonary Disease (COPD) Subjects

NCT00667797

An analysis of the costs and outcomes associated with hospitalization and treatment of Levalbuterol versus Racemic Albuterol in subjects with Asthma and COPD.

Sumitomo Pharma America, Inc.486 participantsStarted Mar 2003

Birmingham, Alabama, United States • Chula Vista, California, United States • Oakland, California, United States +15 more locations

COMPLETEDPhase 4402 miles

Safety of Ramelteon in Elderly Subjects

NCT00568789

The purpose of this study is to investigate the effects of ramelteon in elderly subjects on balance, mobility and memory impairment after awakening in the middle of the night following bedtime dosing.

Takeda33 participantsStarted Jun 2006

Costa Mesa, California, United States • San Diego, California, United States • Miami, Florida, United States +3 more locations

COMPLETEDPhase 2467 miles

Safety and Tolerability Study of Levalbuterol HFA Compared to Racemic Albuterol HFA in Subjects With Asthma

NCT00685022

The purpose of this study is to compare the safety and tolerability of levalbuterol HFA metered dose inhaler (MDI) versus racemic albuterol HFA MDI.

Sumitomo Pharma America, Inc.49 participantsStarted Jun 2003

Encinitas, California, United States • North Dartmouth, Massachusetts, United States • St Louis, Missouri, United States

COMPLETEDPhase 2467 miles

A Safety and Tolerability Study of Levalbuterol HFA Metered Dose Inhaler in Subjects With Asthma

NCT00684827

The purpose of this study is to compare the safety and tolerability of levalbuterol HFA metered dose inhaler (MDI) versus racemic albuterol HFA MDI.

Sumitomo Pharma America, Inc.32 participantsStarted Oct 2002

Encinitas, California, United States • Los Angeles, California, United States • North Dartmouth, Massachusetts, United States +1 more locations

PreviousPage 924 of 991Next

in Atlanta

Heart Diseasein Atlanta